UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 17, 2015
OREXIGEN THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-33415 | 65-1178822 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA |
92037 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (858) 875-8600
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement
On August 17, 2015, Orexigen Therapeutics, Inc. (the “Company”) entered into a Third Amendment to Lease (the “Amendment”) of its lease of office space at 3344 North Torrey Pines Court, La Jolla, California 92037, the Company’s corporate headquarters, with Mullrock 3 Torrey Pines, LLC (the “Landlord”). Pursuant to the Amendment, the Company added an additional 7,706 square feet of space in the same office complex as its corporate headquarters (the “Additional Space”). The Amendment provides for, among other things, monthly rent for the Additional Space, in the amounts set forth in the table below. This monthly rent will begin as of the date of substantial completion of the tenant improvements of the Additional Space, currently expected to occur in the fourth quarter of 2015.
| Months |
Monthly Basic Rent | |
| 1-12 |
$31,209.30 | |
| 13-23 |
$32,134.02 |
In addition, the Landlord agreed to pay for and coordinate basic tenant improvements to the Additional Space.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the Amendment, a copy of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OREXIGEN THERAPEUTICS, INC. | ||||||
| Date: August 21, 2015 | By: | /s/ Joseph P. Hagan | ||||
| Name: | Joseph P. Hagan | |||||
| Title: | Chief Business and Financial Officer | |||||